YOUR ENERGY SYSTEMS, LLC Patent applications |
Patent application number | Title | Published |
20150374626 | TREATMENT OF EVOLVING BACTERIAL RESISTANCE DISEASES INCLUDING KLEBSIELLA PNEUMONIAE WITH LIPOSOMALLY FORMULATED GLUTATHIONE - The composition of the invention, liposomal glutathione, has been recently shown to have utility for having an antibiotic like effect on | 12-31-2015 |
20150366933 | TREATMENT OF KLEBSIELLA PNEUMONIAE WITH LIPOSOMALLY FORMULATED GLUTATHIONE - The composition of the invention, liposomal glutathione, has been recently shown to have utility for having an antibiotic like effect on | 12-24-2015 |
20140193485 | ORALLY ADMINISTRABLE LIPOSOMALLY ENCAPSULATED REDUCED GLUTATHIONE, WITH ACE INHIBITORS FOR REVERSAL AND PREVENTION OF OXIDATION OF CHOLESTEROL AND OF LOW DENSITY LIPOPROTEIN - The invention proposes the combination of reduced glutathione in a liposome (liposomal reduced glutathione) with a specified concentration of reduced glutathione within the liposome for the oral administration of a therapeutically effective amount to ameliorate the progression of vascular disease, including atherosclerosis, diabetes, hypertension, narrowing of arteries leading to decreased blood flow, ischemic events, and the formation of blood clots, abnormal platelet aggregation, and thrombotic events, by reducing the amount and effect of oxidized cholesterol, oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with ACE inhibitors in order to improve the effect of lowering not only cholesterol but also the oxidized cholesterol as well as oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with lisinopril in particular. | 07-10-2014 |
20140141071 | ORALLY ADMINISTRABLE LIPOSOMALLY ENCAPSULATED REDUCED GLUTATHIONE, WITH N-O ENHANCING COMPOUNDS FOR REVERSAL AND PREVENTION OF OXIDATION OF CHOLESTEROL AND OF LOW DENSITY LIPOPROTEIN - The invention proposes the sure of reduced glutathione in a liposome (liposomal reduced glutathione) for the oral administration of a therapeutically effective amount to ameliorate the progression of vascular disease, including atherosclerosis, diabetes, hypertension, narrowing of arteries leading to decreased blood flow, ischemic events, and the formation of blood clots, abnormal platelet aggregation, and thrombotic events, by reducing the amount and effect of oxidized cholesterol, oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with statin drugs to improve the effect of lowering not only cholesterol but also the oxidized cholesterol as well as oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with CoQ10 as a therapy for vascular disease and management of side effects of statin therapy. | 05-22-2014 |
20130129815 | LIPOSOMAL FORMULATION FOR ORAL ADMINISTRATION OF GLUTATHIONE (REDUCED) VIA GEL CAPSULE - The invention is a composition administrable orally to provide systemic glutathione (reduced) and a method for providing systemic glutathione by oral administration of glutathione (reduced) in a liposome encapsulation in a gel cap. The administration of a therapeutically effective amount of oral liposomal glutathione (reduced) results in improvement of symptoms in disease states related to glutathione deficiency such as Parkinson's disease and cystic fibrosis. Compounds enhancing the effect of the liposomal glutathione are contemplated such as Selenium, EDTA, carbidopa, and levodopa. | 05-23-2013 |
20120219616 | LIPOSOMAL REDUCED GLUTATHIONE AND l-ARGININE, INCLUDING WITH OTHER INGREDIENT(S), CAPABLE OF MULTIPATH ADMINISTRATION FOR REVERSAL AND PREVENTION OF OBESITY AND FOR MITOCHONDRIAL BIOGENESIS - The invention enables management of mammalian disease related to decreased energy production in the mitochondria by a combination of liposomal reduced glutathione and 1-arginine. For individuals whose inability to lose weight is related to inefficiency of the biochemical pathways facilitating mitochondrial function and energy production, the invention proposes to assist in weight loss by improving the inefficient production of energy by the respiratory transport chain of mitochondria. The invention is useful for the management of the metabolic syndrome, a group of metabolic factors associated with an increased risk of vascular disease problems. The invention is also useful for the resolution of fatigue that accompanies both weight gain and illnesses. The ability of the invention to increase the production of the biochemical agmatine in the central nervous system as well as generally in the body is part of the benefit of the combination of liposomal reduced glutathione and 1-arginine. | 08-30-2012 |